Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients
NCT06385964Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing SHR-4597 with Placebo (2 arms). Primary endpoints: Incidence and severity of inhalant adverse events in healthy subjects at 4 days and Incidence and severity of inhalant adverse events in asthmatic patients at 16 days. Started May 2024; status: completed.
02
Drugs
SHR-4597
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06385964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385964.